https://www.wikidoc.org/api.php?action=feedrecentchanges&days=7&feedformat=atom&hidebots=1&limit=50&target=Category%3ACS1_maint%3A_Explicit_use_of_et_al.&urlversion=1
wikidoc - Changes related to "Category:CS1 maint: Explicit use of et al." [en]
2026-05-19T12:27:47Z
Related changes
MediaWiki 1.45.1
https://www.wikidoc.org/index.php?title=Ischemic_stroke_medical_therapy&diff=1744239&oldid=1744221
Ischemic stroke medical therapy
2026-05-18T19:59:42Z
<p></p>
<table style="background-color: #fff; color: #202122;" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="en">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 19:59, 18 May 2026</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l26">Line 26:</td>
<td colspan="2" class="diff-lineno">Line 26:</td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>*[[Alteplase|IV alteplase]] is recommended for selected patients who can be treated within 3-4.5 hours of [[ischemic stroke]] [[symptom]] [[onset]] or patient last known well or at [[Baseline (medicine)|baseline]] state.<ref name="LeesEmberson2016">{{cite journal|last1=Lees|first1=Kennedy R.|last2=Emberson|first2=Jonathan|last3=Blackwell|first3=Lisa|last4=Bluhmki|first4=Erich|last5=Davis|first5=Stephen M.|last6=Donnan|first6=Geoffrey A.|last7=Grotta|first7=James C.|last8=Kaste|first8=Markku|last9=von Kummer|first9=Rüdiger|last10=Lansberg|first10=Maarten G.|last11=Lindley|first11=Richard I.|last12=Lyden|first12=Patrick|last13=Murray|first13=Gordon D.|last14=Sandercock|first14=Peter A.G.|last15=Toni|first15=Danilo|last16=Toyoda|first16=Kazunori|last17=Wardlaw|first17=Joanna M.|last18=Whiteley|first18=William N.|last19=Baigent|first19=Colin|last20=Hacke|first20=Werner|last21=Howard|first21=George|last22=Marler|first22=John|last23=Halls|first23=Heather|last24=Holland|first24=Lisa|last25=Mathews|first25=Clare|last26=Smith|first26=Samantha|last27=Wilson|first27=Kate|last28=Koga|first28=Masatoshi|last29=Albers|first29=Gregory|last30=Brott|first30=Thomas|last31=Cohen|first31=Geoffrey|last32=Koga|first32=Masatoshi|last33=Olivot|first33=Jean Marc|last34=Parsons|first34=Mark|last35=Tilley|first35=Barbara|last36=Wahlgren|first36=Nils|last37=del Zoppo|first37=Gregory J|title=Effects of Alteplase for Acute Stroke on the Distribution of Functional Outcomes|journal=Stroke|volume=47|issue=9|year=2016|pages=2373–2379|issn=0039-2499|doi=10.1161/STROKEAHA.116.013644}}</ref><ref name="PowersRabinstein2019" /><ref>{{cite journal|title=The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial|journal=The Lancet|volume=379|issue=9834|year=2012|pages=2352–2363|issn=01406736|doi=10.1016/S0140-6736(12)60768-5}}</ref></div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>*[[Alteplase|IV alteplase]] is recommended for selected patients who can be treated within 3-4.5 hours of [[ischemic stroke]] [[symptom]] [[onset]] or patient last known well or at [[Baseline (medicine)|baseline]] state.<ref name="LeesEmberson2016">{{cite journal|last1=Lees|first1=Kennedy R.|last2=Emberson|first2=Jonathan|last3=Blackwell|first3=Lisa|last4=Bluhmki|first4=Erich|last5=Davis|first5=Stephen M.|last6=Donnan|first6=Geoffrey A.|last7=Grotta|first7=James C.|last8=Kaste|first8=Markku|last9=von Kummer|first9=Rüdiger|last10=Lansberg|first10=Maarten G.|last11=Lindley|first11=Richard I.|last12=Lyden|first12=Patrick|last13=Murray|first13=Gordon D.|last14=Sandercock|first14=Peter A.G.|last15=Toni|first15=Danilo|last16=Toyoda|first16=Kazunori|last17=Wardlaw|first17=Joanna M.|last18=Whiteley|first18=William N.|last19=Baigent|first19=Colin|last20=Hacke|first20=Werner|last21=Howard|first21=George|last22=Marler|first22=John|last23=Halls|first23=Heather|last24=Holland|first24=Lisa|last25=Mathews|first25=Clare|last26=Smith|first26=Samantha|last27=Wilson|first27=Kate|last28=Koga|first28=Masatoshi|last29=Albers|first29=Gregory|last30=Brott|first30=Thomas|last31=Cohen|first31=Geoffrey|last32=Koga|first32=Masatoshi|last33=Olivot|first33=Jean Marc|last34=Parsons|first34=Mark|last35=Tilley|first35=Barbara|last36=Wahlgren|first36=Nils|last37=del Zoppo|first37=Gregory J|title=Effects of Alteplase for Acute Stroke on the Distribution of Functional Outcomes|journal=Stroke|volume=47|issue=9|year=2016|pages=2373–2379|issn=0039-2499|doi=10.1161/STROKEAHA.116.013644}}</ref><ref name="PowersRabinstein2019" /><ref>{{cite journal|title=The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial|journal=The Lancet|volume=379|issue=9834|year=2012|pages=2352–2363|issn=01406736|doi=10.1016/S0140-6736(12)60768-5}}</ref></div></td></tr>
<tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">*In imaging-selected patients with wake-up stroke/unknown onset or extended-window presentations, IV thrombolysis may be beneficial when selection criteria are met<ref name="pmid41582814">{{cite journal |vauthors=Prabhakaran S, Gonzalez NR, Zachrison KS, Adeoye O, Alexandrov AW, Ansari SA, Chapman S, Czap AL, Dumitrascu OM, Ishida K, Jadhav AP, Johnson B, Johnston KC, Khatri P, Kimberly WT, Lee VH, Leslie-Mazwi TM, Mac Grory B, Madsen TE, Menon B, Mistry EA, Park S, Parker S, Pérez de la Ossa N, Reeves M, Saiz T, Scott PA, Schwartzberg D, Sheth SA, Sporns PB, Times S, Tjoumakaris S, Wolfe SQ, Yaghi S |title=2026 Guideline for the Early Management of Patients With Acute Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association |journal=Stroke |volume= |issue= |pages= |date=January 2026 |pmid=41582814 |doi=10.1161/STR.0000000000000513 |url=}}</ref><ref name="pmid31067369">{{cite journal |vauthors=Ma H, Campbell BC, Parsons MW, Churilov L, Levi CR, Hsu C, Kleinig TJ, Wijeratne T, Curtze S, Dewey HM, Miteff F, Tsai CH, Lee JT, Phan TG, Mahant N, Sun MC, Krause M, Sturm J, Grimley R, Chen CH, Hu CJ, Wong AA, Field D, Sun Y, Barber PA, Sabet A, Jannes J, Jeng JS, Clissold B, Markus R, Lin CH, Lien LM, Bladin CF, Christensen S, Yassi N, Sharma G, Bivard A, Desmond PM, Yan B, Mitchell PJ, Thijs V, Carey L, Meretoja A, Davis SM, Donnan GA |title=Thrombolysis Guided by Perfusion Imaging up to 9 Hours after Onset of Stroke |journal=N Engl J Med |volume=380 |issue=19 |pages=1795–1803 |date=May 2019 |pmid=31067369 |doi=10.1056/NEJMoa1813046 |url=}}</ref>.</ins></div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>*The [[dose]] of [[Alteplase|IV alteplase]] is 0.9 mg/kg (maximum dose 90 mg) over 60 min, with 10% of the [[dose]] given as a [[bolus]] over 1 min.<ref name="PowersRabinstein2019" /></div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>*The [[dose]] of [[Alteplase|IV alteplase]] is 0.9 mg/kg (maximum dose 90 mg) over 60 min, with 10% of the [[dose]] given as a [[bolus]] over 1 min.<ref name="PowersRabinstein2019" /></div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>*[[Alteplase|IV alteplase]] should be initiated as soon as possible, having been demonstrated better outcomes the sooner is administered.<ref name="PowersRabinstein2019" /></div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>*[[Alteplase|IV alteplase]] should be initiated as soon as possible, having been demonstrated better outcomes the sooner is administered.<ref name="PowersRabinstein2019" /></div></td></tr>
<tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l40">Line 40:</td>
<td colspan="2" class="diff-lineno">Line 41:</td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>====Tenecteplase====</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>====Tenecteplase====</div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>*[[Tenecteplase]] <del style="font-weight: bold; text-decoration: none;">may be useful </del>in patients <del style="font-weight: bold; text-decoration: none;">with minor [[neurological]] impairment.</del><ref name="<del style="font-weight: bold; text-decoration: none;">HuangCheripelli2015</del>">{{cite journal|<del style="font-weight: bold; text-decoration: none;">last1</del>=<del style="font-weight: bold; text-decoration: none;">Huang</del>|<del style="font-weight: bold; text-decoration: none;">first1</del>=<del style="font-weight: bold; text-decoration: none;">Xuya</del>|<del style="font-weight: bold; text-decoration: none;">last2</del>=<del style="font-weight: bold; text-decoration: none;">Cheripelli</del>|<del style="font-weight: bold; text-decoration: none;">first2</del>=<del style="font-weight: bold; text-decoration: none;">Bharath Kumar</del>|<del style="font-weight: bold; text-decoration: none;">last3</del>=<del style="font-weight: bold; text-decoration: none;">Lloyd</del>|<del style="font-weight: bold; text-decoration: none;">first3</del>=<del style="font-weight: bold; text-decoration: none;">Suzanne M</del>|<del style="font-weight: bold; text-decoration: none;">last4</del>=<del style="font-weight: bold; text-decoration: none;">Kalladka</del>|<del style="font-weight: bold; text-decoration: none;">first4</del>=<del style="font-weight: bold; text-decoration: none;">Dheeraj</del>|<del style="font-weight: bold; text-decoration: none;">last5</del>=<del style="font-weight: bold; text-decoration: none;">Moreton</del>|<del style="font-weight: bold; text-decoration: none;">first5</del>=<del style="font-weight: bold; text-decoration: none;">Fiona Catherine|last6</del>=<del style="font-weight: bold; text-decoration: none;">Siddiqui</del>|<del style="font-weight: bold; text-decoration: none;">first6</del>=<del style="font-weight: bold; text-decoration: none;">Aslam|last7=Ford|first7=Ian|last8=Muir|first8=Keith W</del>|title=<del style="font-weight: bold; text-decoration: none;">Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST)</del>: <del style="font-weight: bold; text-decoration: none;">a phase 2, randomised, open-label, blinded endpoint study</del>|journal=<del style="font-weight: bold; text-decoration: none;">The Lancet Neurology</del>|volume=<del style="font-weight: bold; text-decoration: none;">14</del>|issue=<del style="font-weight: bold; text-decoration: none;">4</del>|<del style="font-weight: bold; text-decoration: none;">year</del>=<del style="font-weight: bold; text-decoration: none;">2015</del>|<del style="font-weight: bold; text-decoration: none;">pages</del>=<del style="font-weight: bold; text-decoration: none;">368–376</del>|<del style="font-weight: bold; text-decoration: none;">issn</del>=<del style="font-weight: bold; text-decoration: none;">14744422</del>|doi=10.1016/<del style="font-weight: bold; text-decoration: none;">S1474-4422(15)70017-7</del>}}</ref></div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>*[[Tenecteplase]] <ins style="font-weight: bold; text-decoration: none;">is a reasonable alternative to alteplase for IV thrombolysis </ins>in <ins style="font-weight: bold; text-decoration: none;">eligible acute ischemic stroke </ins>patients <ins style="font-weight: bold; text-decoration: none;">and is administered as a single IV bolus </ins><ref name="<ins style="font-weight: bold; text-decoration: none;">pmid41582814</ins>">{{cite journal |<ins style="font-weight: bold; text-decoration: none;">vauthors</ins>=<ins style="font-weight: bold; text-decoration: none;">Prabhakaran S, Gonzalez NR, Zachrison KS, Adeoye O, Alexandrov AW, Ansari SA, Chapman S, Czap AL, Dumitrascu OM, Ishida K, Jadhav AP, Johnson B, Johnston KC, Khatri P, Kimberly WT, Lee VH, Leslie-Mazwi TM, Mac Grory B, Madsen TE, Menon B, Mistry EA, Park S, Parker S, Pérez de la Ossa N, Reeves M, Saiz T, Scott PA, Schwartzberg D, Sheth SA, Sporns PB, Times S, Tjoumakaris S, Wolfe SQ, Yaghi S </ins>|<ins style="font-weight: bold; text-decoration: none;">title</ins>=<ins style="font-weight: bold; text-decoration: none;">2026 Guideline for the Early Management of Patients With Acute Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association </ins>|<ins style="font-weight: bold; text-decoration: none;">journal</ins>=<ins style="font-weight: bold; text-decoration: none;">Stroke </ins>|<ins style="font-weight: bold; text-decoration: none;">volume</ins>= |<ins style="font-weight: bold; text-decoration: none;">issue</ins>= |<ins style="font-weight: bold; text-decoration: none;">pages</ins>= |<ins style="font-weight: bold; text-decoration: none;">date</ins>=<ins style="font-weight: bold; text-decoration: none;">January 2026 </ins>|<ins style="font-weight: bold; text-decoration: none;">pmid</ins>=<ins style="font-weight: bold; text-decoration: none;">41582814 </ins>|<ins style="font-weight: bold; text-decoration: none;">doi</ins>=<ins style="font-weight: bold; text-decoration: none;">10.1161/STR.0000000000000513 </ins>|<ins style="font-weight: bold; text-decoration: none;">url</ins>=<ins style="font-weight: bold; text-decoration: none;">}}</ref><ref name</ins>=<ins style="font-weight: bold; text-decoration: none;">"pmid37479410">{{cite journal </ins>|<ins style="font-weight: bold; text-decoration: none;">vauthors</ins>=<ins style="font-weight: bold; text-decoration: none;">Lo BM, Carpenter CR, Ducey S, Gottlieb M, Kaji A, Diercks DB, Diercks DB, Wolf SJ, Anderson JD, Byyny R, Carpenter CR, Friedman B, Gemme SR, Gerardo CJ, Godwin SA, Hahn SA, Hatten BW, Haukoos JS, Kaji A, Kwok H, Lo BM, Mace SE, Moran M, Promes SB, Shah KH, Shih RD, Silvers SM, Slivinski A, Smith MD, Thiessen ME, Tomaszewski CA, Trent S, Valente JH, Wall SP, Westafer LM, Yu Y, Cantrill SV, Finnell JT, Schulz T, Vandertulip K </ins>|title=<ins style="font-weight: bold; text-decoration: none;">Clinical Policy</ins>: <ins style="font-weight: bold; text-decoration: none;">Critical Issues in the Management of Adult Patients Presenting to the Emergency Department With Acute Ischemic Stroke </ins>|journal=<ins style="font-weight: bold; text-decoration: none;">Ann Emerg Med </ins>|volume=<ins style="font-weight: bold; text-decoration: none;">82 </ins>|issue=<ins style="font-weight: bold; text-decoration: none;">2 </ins>|<ins style="font-weight: bold; text-decoration: none;">pages</ins>=<ins style="font-weight: bold; text-decoration: none;">e17–e64 </ins>|<ins style="font-weight: bold; text-decoration: none;">date</ins>=<ins style="font-weight: bold; text-decoration: none;">August 2023 </ins>|<ins style="font-weight: bold; text-decoration: none;">pmid</ins>=<ins style="font-weight: bold; text-decoration: none;">37479410 </ins>|doi=10.1016/<ins style="font-weight: bold; text-decoration: none;">j.annemergmed.2023.03.007 |url=</ins>}}</ref></div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>*The dose of [[tenecteplase]] is <del style="font-weight: bold; text-decoration: none;">a single IV [[bolus]] of </del>0.25<del style="font-weight: bold; text-decoration: none;">-</del>mg/kg (maximum 25 mg).<ref name="<del style="font-weight: bold; text-decoration: none;">CampbellMitchell2018</del>">{{cite journal|<del style="font-weight: bold; text-decoration: none;">last1</del>=<del style="font-weight: bold; text-decoration: none;">Campbell</del>|<del style="font-weight: bold; text-decoration: none;">first1</del>=<del style="font-weight: bold; text-decoration: none;">Bruce C.V.</del>|<del style="font-weight: bold; text-decoration: none;">last2</del>=<del style="font-weight: bold; text-decoration: none;">Mitchell</del>|<del style="font-weight: bold; text-decoration: none;">first2</del>=<del style="font-weight: bold; text-decoration: none;">Peter J.</del>|<del style="font-weight: bold; text-decoration: none;">last3</del>=<del style="font-weight: bold; text-decoration: none;">Churilov</del>|<del style="font-weight: bold; text-decoration: none;">first3</del>=<del style="font-weight: bold; text-decoration: none;">Leonid</del>|<del style="font-weight: bold; text-decoration: none;">last4</del>=<del style="font-weight: bold; text-decoration: none;">Yassi</del>|<del style="font-weight: bold; text-decoration: none;">first4</del>=<del style="font-weight: bold; text-decoration: none;">Nawaf</del>|<del style="font-weight: bold; text-decoration: none;">last5</del>=<del style="font-weight: bold; text-decoration: none;">Kleinig</del>|<del style="font-weight: bold; text-decoration: none;">first5</del>=<del style="font-weight: bold; text-decoration: none;">Timothy J</del>.|<del style="font-weight: bold; text-decoration: none;">last6</del>=Dowling<del style="font-weight: bold; text-decoration: none;">|first6=Richard J.|last7=</del>Yan<del style="font-weight: bold; text-decoration: none;">|first7=Bernard|last8=</del>Bush<del style="font-weight: bold; text-decoration: none;">|first8=Steven J.|last9=</del>Dewey<del style="font-weight: bold; text-decoration: none;">|first9=Helen M.|last10=</del>Thijs<del style="font-weight: bold; text-decoration: none;">|first10=Vincent|last11=</del>Scroop<del style="font-weight: bold; text-decoration: none;">|first11=Rebecca|last12=</del>Simpson<del style="font-weight: bold; text-decoration: none;">|first12=Marion|last13=</del>Brooks<del style="font-weight: bold; text-decoration: none;">|first13=Mark|last14=</del>Asadi<del style="font-weight: bold; text-decoration: none;">|first14=Hamed|last15=</del>Wu<del style="font-weight: bold; text-decoration: none;">|first15=Teddy Y.|last16=</del>Shah<del style="font-weight: bold; text-decoration: none;">|first16=Darshan G.|last17=</del>Wijeratne<del style="font-weight: bold; text-decoration: none;">|first17=Tissa|last18=</del>Ang<del style="font-weight: bold; text-decoration: none;">|first18=Timothy|last19=</del>Miteff<del style="font-weight: bold; text-decoration: none;">|first19=Ferdinand|last20=</del>Levi<del style="font-weight: bold; text-decoration: none;">|first20=Christopher R.|last21=</del>Rodrigues<del style="font-weight: bold; text-decoration: none;">|first21=Edrich|last22=</del>Zhao<del style="font-weight: bold; text-decoration: none;">|first22=Henry|last23=</del>Salvaris<del style="font-weight: bold; text-decoration: none;">|first23=Patrick|last24=</del>Garcia-Esperon<del style="font-weight: bold; text-decoration: none;">|first24=Carlos|last25=</del>Bailey<del style="font-weight: bold; text-decoration: none;">|first25=Peter|last26=</del>Rice<del style="font-weight: bold; text-decoration: none;">|first26=Henry|last27=</del>de Villiers<del style="font-weight: bold; text-decoration: none;">|first27=Laetitia|last28=</del>Brown<del style="font-weight: bold; text-decoration: none;">|first28=Helen|last29=</del>Redmond<del style="font-weight: bold; text-decoration: none;">|first29=Kendal|last30=</del>Leggett<del style="font-weight: bold; text-decoration: none;">|first30=David|last31=</del>Fink<del style="font-weight: bold; text-decoration: none;">|first31=John N.|last32=</del>Collecutt<del style="font-weight: bold; text-decoration: none;">|first32=Wayne|last33=</del>Wong<del style="font-weight: bold; text-decoration: none;">|first33=Andrew A.|last34=</del>Muller<del style="font-weight: bold; text-decoration: none;">|first34=Claire|last35=</del>Coulthard<del style="font-weight: bold; text-decoration: none;">|first35=Alan|last36=</del>Mitchell<del style="font-weight: bold; text-decoration: none;">|first36=Ken|last37=</del>Clouston<del style="font-weight: bold; text-decoration: none;">|first37=John|last38=</del>Mahady<del style="font-weight: bold; text-decoration: none;">|first38=Kate|last39=</del>Field<del style="font-weight: bold; text-decoration: none;">|first39=Deborah|last40=</del>Ma<del style="font-weight: bold; text-decoration: none;">|first40=Henry|last41=</del>Phan<del style="font-weight: bold; text-decoration: none;">|first41=Thanh G.|last42=</del>Chong<del style="font-weight: bold; text-decoration: none;">|first42=Winston|last43=</del>Chandra<del style="font-weight: bold; text-decoration: none;">|first43=Ronil V.|last44=</del>Slater<del style="font-weight: bold; text-decoration: none;">|first44=Lee-Anne|last45=</del>Krause<del style="font-weight: bold; text-decoration: none;">|first45=Martin|last46=</del>Harrington<del style="font-weight: bold; text-decoration: none;">|first46=Timothy J.|last47=</del>Faulder|<del style="font-weight: bold; text-decoration: none;">first47</del>=<del style="font-weight: bold; text-decoration: none;">Kenneth C.</del>|<del style="font-weight: bold; text-decoration: none;">last48</del>=<del style="font-weight: bold; text-decoration: none;">Steinfort</del>|<del style="font-weight: bold; text-decoration: none;">first48</del>=<del style="font-weight: bold; text-decoration: none;">Brendan S.</del>|<del style="font-weight: bold; text-decoration: none;">last49</del>=<del style="font-weight: bold; text-decoration: none;">Bladin</del>|<del style="font-weight: bold; text-decoration: none;">first49</del>=<del style="font-weight: bold; text-decoration: none;">Christopher F.</del>|<del style="font-weight: bold; text-decoration: none;">last50</del>=<del style="font-weight: bold; text-decoration: none;">Sharma</del>|<del style="font-weight: bold; text-decoration: none;">first50</del>=<del style="font-weight: bold; text-decoration: none;">Gagan</del>|<del style="font-weight: bold; text-decoration: none;">last51</del>=<del style="font-weight: bold; text-decoration: none;">Desmond|first51=Patricia M</del>.|<del style="font-weight: bold; text-decoration: none;">last52</del>=<del style="font-weight: bold; text-decoration: none;">Parsons|first52=Mark W</del>.<del style="font-weight: bold; text-decoration: none;">|last53</del>=<del style="font-weight: bold; text-decoration: none;">Donnan</del>|<del style="font-weight: bold; text-decoration: none;">first53</del>=<del style="font-weight: bold; text-decoration: none;">Geoffrey </del>A<del style="font-weight: bold; text-decoration: none;">.|last54=Davis|first54=Stephen </del>M<del style="font-weight: bold; text-decoration: none;">.</del>|title=Tenecteplase <del style="font-weight: bold; text-decoration: none;">versus Alteplase before Thrombectomy </del>for Ischemic Stroke|journal=<del style="font-weight: bold; text-decoration: none;">New England Journal of Medicine</del>|volume=<del style="font-weight: bold; text-decoration: none;">378</del>|issue=<del style="font-weight: bold; text-decoration: none;">17</del>|<del style="font-weight: bold; text-decoration: none;">year</del>=<del style="font-weight: bold; text-decoration: none;">2018</del>|<del style="font-weight: bold; text-decoration: none;">pages</del>=<del style="font-weight: bold; text-decoration: none;">1573–1582</del>|<del style="font-weight: bold; text-decoration: none;">issn</del>=<del style="font-weight: bold; text-decoration: none;">0028-4793</del>|doi=10.1056/<del style="font-weight: bold; text-decoration: none;">NEJMoa1716405</del>}}</ref></div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>*The dose of [[tenecteplase]] is 0.25 mg/kg <ins style="font-weight: bold; text-decoration: none;">IV bolus </ins>(maximum 25 mg).<ref name="<ins style="font-weight: bold; text-decoration: none;">pmid37479410</ins>">{{cite journal |<ins style="font-weight: bold; text-decoration: none;">vauthors</ins>=<ins style="font-weight: bold; text-decoration: none;">Lo BM, Carpenter CR, Ducey S, Gottlieb M, Kaji A, Diercks DB, Diercks DB, Wolf SJ, Anderson JD, Byyny R, Carpenter CR, Friedman B, Gemme SR, Gerardo CJ, Godwin SA, Hahn SA, Hatten BW, Haukoos JS, Kaji A, Kwok H, Lo BM, Mace SE, Moran M, Promes SB, Shah KH, Shih RD, Silvers SM, Slivinski A, Smith MD, Thiessen ME, Tomaszewski CA, Trent S, Valente JH, Wall SP, Westafer LM, Yu Y, Cantrill SV, Finnell JT, Schulz T, Vandertulip K </ins>|<ins style="font-weight: bold; text-decoration: none;">title</ins>=<ins style="font-weight: bold; text-decoration: none;">Clinical Policy: Critical Issues in the Management of Adult Patients Presenting to the Emergency Department With Acute Ischemic Stroke </ins>|<ins style="font-weight: bold; text-decoration: none;">journal</ins>=<ins style="font-weight: bold; text-decoration: none;">Ann Emerg Med </ins>|<ins style="font-weight: bold; text-decoration: none;">volume</ins>=<ins style="font-weight: bold; text-decoration: none;">82 </ins>|<ins style="font-weight: bold; text-decoration: none;">issue</ins>=<ins style="font-weight: bold; text-decoration: none;">2 </ins>|<ins style="font-weight: bold; text-decoration: none;">pages</ins>=<ins style="font-weight: bold; text-decoration: none;">e17–e64 </ins>|<ins style="font-weight: bold; text-decoration: none;">date</ins>=<ins style="font-weight: bold; text-decoration: none;">August 2023 </ins>|<ins style="font-weight: bold; text-decoration: none;">pmid</ins>=<ins style="font-weight: bold; text-decoration: none;">37479410 </ins>|<ins style="font-weight: bold; text-decoration: none;">doi</ins>=<ins style="font-weight: bold; text-decoration: none;">10.1016/j.annemergmed.2023.03.007 </ins>|<ins style="font-weight: bold; text-decoration: none;">url</ins>=<ins style="font-weight: bold; text-decoration: none;">}}</ref></ins></div></td></tr>
<tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">*Among patients with LVO planned for thrombectomy, tenecteplase (0.25 mg/kg) achieved higher early reperfusion than alteplase (22% vs 10%) and improved 90-day functional outcome (median mRS 2 vs 3) with similar symptomatic ICH (1% vs 1%) in EXTEND-IA TNK</ins>.<ins style="font-weight: bold; text-decoration: none;"><ref name="pmid29694815">{{cite journal </ins>|<ins style="font-weight: bold; text-decoration: none;">vauthors</ins>=<ins style="font-weight: bold; text-decoration: none;">Campbell BC, Mitchell PJ, Churilov L, Yassi N, Kleinig TJ, </ins>Dowling <ins style="font-weight: bold; text-decoration: none;">RJ, </ins>Yan <ins style="font-weight: bold; text-decoration: none;">B, </ins>Bush <ins style="font-weight: bold; text-decoration: none;">SJ, </ins>Dewey <ins style="font-weight: bold; text-decoration: none;">HM, </ins>Thijs <ins style="font-weight: bold; text-decoration: none;">V, </ins>Scroop <ins style="font-weight: bold; text-decoration: none;">R, </ins>Simpson <ins style="font-weight: bold; text-decoration: none;">M, </ins>Brooks <ins style="font-weight: bold; text-decoration: none;">M, </ins>Asadi <ins style="font-weight: bold; text-decoration: none;">H, </ins>Wu <ins style="font-weight: bold; text-decoration: none;">TY, </ins>Shah <ins style="font-weight: bold; text-decoration: none;">DG, </ins>Wijeratne <ins style="font-weight: bold; text-decoration: none;">T, </ins>Ang <ins style="font-weight: bold; text-decoration: none;">T, </ins>Miteff <ins style="font-weight: bold; text-decoration: none;">F, </ins>Levi <ins style="font-weight: bold; text-decoration: none;">CR, </ins>Rodrigues <ins style="font-weight: bold; text-decoration: none;">E, </ins>Zhao <ins style="font-weight: bold; text-decoration: none;">H, </ins>Salvaris <ins style="font-weight: bold; text-decoration: none;">P, </ins>Garcia-Esperon <ins style="font-weight: bold; text-decoration: none;">C, </ins>Bailey <ins style="font-weight: bold; text-decoration: none;">P, </ins>Rice <ins style="font-weight: bold; text-decoration: none;">H, </ins>de Villiers <ins style="font-weight: bold; text-decoration: none;">L, </ins>Brown <ins style="font-weight: bold; text-decoration: none;">H, </ins>Redmond <ins style="font-weight: bold; text-decoration: none;">K, </ins>Leggett <ins style="font-weight: bold; text-decoration: none;">D, </ins>Fink <ins style="font-weight: bold; text-decoration: none;">JN, </ins>Collecutt <ins style="font-weight: bold; text-decoration: none;">W, </ins>Wong <ins style="font-weight: bold; text-decoration: none;">AA, </ins>Muller <ins style="font-weight: bold; text-decoration: none;">C, </ins>Coulthard <ins style="font-weight: bold; text-decoration: none;">A, </ins>Mitchell <ins style="font-weight: bold; text-decoration: none;">K, </ins>Clouston <ins style="font-weight: bold; text-decoration: none;">J, </ins>Mahady <ins style="font-weight: bold; text-decoration: none;">K, </ins>Field <ins style="font-weight: bold; text-decoration: none;">D, </ins>Ma <ins style="font-weight: bold; text-decoration: none;">H, </ins>Phan <ins style="font-weight: bold; text-decoration: none;">TG, </ins>Chong <ins style="font-weight: bold; text-decoration: none;">W, </ins>Chandra <ins style="font-weight: bold; text-decoration: none;">RV, </ins>Slater <ins style="font-weight: bold; text-decoration: none;">LA, </ins>Krause <ins style="font-weight: bold; text-decoration: none;">M, </ins>Harrington <ins style="font-weight: bold; text-decoration: none;">TJ, </ins>Faulder <ins style="font-weight: bold; text-decoration: none;">KC, Steinfort BS, Bladin CF, Sharma G, Desmond PM, Parsons MW, Donnan GA, Davis SM </ins>|<ins style="font-weight: bold; text-decoration: none;">title</ins>=<ins style="font-weight: bold; text-decoration: none;">Tenecteplase versus Alteplase before Thrombectomy for Ischemic Stroke </ins>|<ins style="font-weight: bold; text-decoration: none;">journal</ins>=<ins style="font-weight: bold; text-decoration: none;">N Engl J Med </ins>|<ins style="font-weight: bold; text-decoration: none;">volume</ins>=<ins style="font-weight: bold; text-decoration: none;">378 </ins>|<ins style="font-weight: bold; text-decoration: none;">issue</ins>=<ins style="font-weight: bold; text-decoration: none;">17 </ins>|<ins style="font-weight: bold; text-decoration: none;">pages</ins>=<ins style="font-weight: bold; text-decoration: none;">1573–1582 </ins>|<ins style="font-weight: bold; text-decoration: none;">date</ins>=<ins style="font-weight: bold; text-decoration: none;">April 2018 </ins>|<ins style="font-weight: bold; text-decoration: none;">pmid</ins>=<ins style="font-weight: bold; text-decoration: none;">29694815 </ins>|<ins style="font-weight: bold; text-decoration: none;">doi</ins>=<ins style="font-weight: bold; text-decoration: none;">10</ins>.<ins style="font-weight: bold; text-decoration: none;">1056/NEJMoa1716405 </ins>|<ins style="font-weight: bold; text-decoration: none;">url</ins>=<ins style="font-weight: bold; text-decoration: none;">}}</ref></ins></div></td></tr>
<tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">*[[Tenecteplase]] has also shown benefit in selected patients treated 4</ins>.<ins style="font-weight: bold; text-decoration: none;">5–24 hours after onset when thrombectomy is not available in TRACE-III<ref name</ins>=<ins style="font-weight: bold; text-decoration: none;">"pmid38884324">{{cite journal </ins>|<ins style="font-weight: bold; text-decoration: none;">vauthors</ins>=<ins style="font-weight: bold; text-decoration: none;">Xiong Y, Campbell BC, Schwamm LH, Meng X, Jin A, Parsons MW, Fisher M, Jiang Y, Che F, Wang L, Zhou L, Dai H, Liu X, Pan Y, Duan C, Xu Y, Xu </ins>A<ins style="font-weight: bold; text-decoration: none;">, Zong L, Tan Z, Ye W, Wang H, Wang Z, Hao </ins>M<ins style="font-weight: bold; text-decoration: none;">, Cao Z, Wang L, Wu S, Li H, Li Z, Zhao X, Wang Y </ins>|title=Tenecteplase for Ischemic Stroke <ins style="font-weight: bold; text-decoration: none;">at 4.5 to 24 Hours without Thrombectomy </ins>|journal=<ins style="font-weight: bold; text-decoration: none;">N Engl J Med </ins>|volume=<ins style="font-weight: bold; text-decoration: none;">391 </ins>|issue=<ins style="font-weight: bold; text-decoration: none;">3 </ins>|<ins style="font-weight: bold; text-decoration: none;">pages</ins>=<ins style="font-weight: bold; text-decoration: none;">203–212 </ins>|<ins style="font-weight: bold; text-decoration: none;">date</ins>=<ins style="font-weight: bold; text-decoration: none;">July 2024 </ins>|<ins style="font-weight: bold; text-decoration: none;">pmid</ins>=<ins style="font-weight: bold; text-decoration: none;">38884324 </ins>|doi=10.1056/<ins style="font-weight: bold; text-decoration: none;">NEJMoa2402980 |url=</ins>}}</ref><ins style="font-weight: bold; text-decoration: none;">.</ins></div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>====Antiplatelet therapy====</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>====Antiplatelet therapy====</div></td></tr>
</table>
Hasnain Ali
https://www.wikidoc.org/index.php?title=Ventricular_arrhythmias&diff=1744235&oldid=1061882
Ventricular arrhythmias
2026-05-18T05:18:24Z
<p></p>
<a href="https://www.wikidoc.org/index.php?title=Ventricular_arrhythmias&diff=1744235&oldid=1061882">Show changes</a>
Nehal Eid
https://www.wikidoc.org/index.php?title=Ischemic_stroke_medical_therapy&diff=1744221&oldid=1744153
Ischemic stroke medical therapy
2026-05-17T13:26:26Z
<p></p>
<table style="background-color: #fff; color: #202122;" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="en">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 13:26, 17 May 2026</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l17">Line 17:</td>
<td colspan="2" class="diff-lineno">Line 17:</td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>*The usefulness of [[anticoagulants]] such as [[thrombin]] inhibitors ([[dabigatran]]) and [[factor Xa]] inhibitors ([[rivaroxaban]], [[apixaban]], [[edoxaban]]) is not well established in the acute setting of [[stroke]].<ref name="GioiaKate2016">{{cite journal|last1=Gioia|first1=Laura C.|last2=Kate|first2=Mahesh|last3=Sivakumar|first3=Leka|last4=Hussain|first4=Dulara|last5=Kalashyan|first5=Hayrapet|last6=Buck|first6=Brian|last7=Bussiere|first7=Miguel|last8=Jeerakathil|first8=Thomas|last9=Shuaib|first9=Ashfaq|last10=Emery|first10=Derek|last11=Butcher|first11=Ken|title=Early Rivaroxaban Use After Cardioembolic Stroke May Not Result in Hemorrhagic Transformation|journal=Stroke|volume=47|issue=7|year=2016|pages=1917–1919|issn=0039-2499|doi=10.1161/STROKEAHA.116.013491}}</ref></div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>*The usefulness of [[anticoagulants]] such as [[thrombin]] inhibitors ([[dabigatran]]) and [[factor Xa]] inhibitors ([[rivaroxaban]], [[apixaban]], [[edoxaban]]) is not well established in the acute setting of [[stroke]].<ref name="GioiaKate2016">{{cite journal|last1=Gioia|first1=Laura C.|last2=Kate|first2=Mahesh|last3=Sivakumar|first3=Leka|last4=Hussain|first4=Dulara|last5=Kalashyan|first5=Hayrapet|last6=Buck|first6=Brian|last7=Bussiere|first7=Miguel|last8=Jeerakathil|first8=Thomas|last9=Shuaib|first9=Ashfaq|last10=Emery|first10=Derek|last11=Butcher|first11=Ken|title=Early Rivaroxaban Use After Cardioembolic Stroke May Not Result in Hemorrhagic Transformation|journal=Stroke|volume=47|issue=7|year=2016|pages=1917–1919|issn=0039-2499|doi=10.1161/STROKEAHA.116.013491}}</ref></div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>*The use of [[thrombolysis]] via ultrasound waves concomitant to [[Fibrinolysis|IV fibrinolysis]] is not recommended.<ref name="NacuKvistad2017">{{cite journal|last1=Nacu|first1=Aliona|last2=Kvistad|first2=Christopher E.|last3=Naess|first3=Halvor|last4=Øygarden|first4=Halvor|last5=Logallo|first5=Nicola|last6=Assmus|first6=Jörg|last7=Waje-Andreassen|first7=Ulrike|last8=Kurz|first8=Kathinka D.|last9=Neckelmann|first9=Gesche|last10=Thomassen|first10=Lars|title=NOR-SASS (Norwegian Sonothrombolysis in Acute Stroke Study)|journal=Stroke|volume=48|issue=2|year=2017|pages=335–341|issn=0039-2499|doi=10.1161/STROKEAHA.116.014644}}</ref></div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>*The use of [[thrombolysis]] via ultrasound waves concomitant to [[Fibrinolysis|IV fibrinolysis]] is not recommended.<ref name="NacuKvistad2017">{{cite journal|last1=Nacu|first1=Aliona|last2=Kvistad|first2=Christopher E.|last3=Naess|first3=Halvor|last4=Øygarden|first4=Halvor|last5=Logallo|first5=Nicola|last6=Assmus|first6=Jörg|last7=Waje-Andreassen|first7=Ulrike|last8=Kurz|first8=Kathinka D.|last9=Neckelmann|first9=Gesche|last10=Thomassen|first10=Lars|title=NOR-SASS (Norwegian Sonothrombolysis in Acute Stroke Study)|journal=Stroke|volume=48|issue=2|year=2017|pages=335–341|issn=0039-2499|doi=10.1161/STROKEAHA.116.014644}}</ref></div></td></tr>
<tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">*Tenecteplase (0.25 mg/kg IV bolus; max 25 mg) is an accepted alternative to alteplase (0.9 mg/kg; max 90 mg with 10% bolus then 60-minute infusion) in thrombolysis-eligible patients, ideally using an institutional protocol.<ref name="pmid41582814">{{cite journal |vauthors=Prabhakaran S, Gonzalez NR, Zachrison KS, Adeoye O, Alexandrov AW, Ansari SA, Chapman S, Czap AL, Dumitrascu OM, Ishida K, Jadhav AP, Johnson B, Johnston KC, Khatri P, Kimberly WT, Lee VH, Leslie-Mazwi TM, Mac Grory B, Madsen TE, Menon B, Mistry EA, Park S, Parker S, Pérez de la Ossa N, Reeves M, Saiz T, Scott PA, Schwartzberg D, Sheth SA, Sporns PB, Times S, Tjoumakaris S, Wolfe SQ, Yaghi S |title=2026 Guideline for the Early Management of Patients With Acute Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association |journal=Stroke |volume= |issue= |pages= |date=January 2026 |pmid=41582814 |doi=10.1161/STR.0000000000000513 |url=}}</ref><ref name="pmid37479410">{{cite journal |vauthors=Lo BM, Carpenter CR, Ducey S, Gottlieb M, Kaji A, Diercks DB, Diercks DB, Wolf SJ, Anderson JD, Byyny R, Carpenter CR, Friedman B, Gemme SR, Gerardo CJ, Godwin SA, Hahn SA, Hatten BW, Haukoos JS, Kaji A, Kwok H, Lo BM, Mace SE, Moran M, Promes SB, Shah KH, Shih RD, Silvers SM, Slivinski A, Smith MD, Thiessen ME, Tomaszewski CA, Trent S, Valente JH, Wall SP, Westafer LM, Yu Y, Cantrill SV, Finnell JT, Schulz T, Vandertulip K |title=Clinical Policy: Critical Issues in the Management of Adult Patients Presenting to the Emergency Department With Acute Ischemic Stroke |journal=Ann Emerg Med |volume=82 |issue=2 |pages=e17–e64 |date=August 2023 |pmid=37479410 |doi=10.1016/j.annemergmed.2023.03.007 |url=}}</ref></ins></div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>*High-intensity [[statin]] therapy should be initiated in patients younger than 75 with clinical [[Coronary heart disease|ASCVD]], to achieving a reduction in [[LDL-C]] levels of at least 50%.</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>*High-intensity [[statin]] therapy should be initiated in patients younger than 75 with clinical [[Coronary heart disease|ASCVD]], to achieving a reduction in [[LDL-C]] levels of at least 50%.</div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>*In patients older than 75 years of age with clinical [[Coronary heart disease|ASCVD]], it is reasonable to initiate moderate or high-intensity [[statin]] therapy after reviewing [[adverse effects]] and [[Drug interaction|drug interactions]].<ref name="PowersRabinstein2019">{{cite journal|last1=Powers|first1=William J.|last2=Rabinstein|first2=Alejandro A.|last3=Ackerson|first3=Teri|last4=Adeoye|first4=Opeolu M.|last5=Bambakidis|first5=Nicholas C.|last6=Becker|first6=Kyra|last7=Biller|first7=José|last8=Brown|first8=Michael|last9=Demaerschalk|first9=Bart M.|last10=Hoh|first10=Brian|last11=Jauch|first11=Edward C.|last12=Kidwell|first12=Chelsea S.|last13=Leslie-Mazwi|first13=Thabele M.|last14=Ovbiagele|first14=Bruce|last15=Scott|first15=Phillip A.|last16=Sheth|first16=Kevin N.|last17=Southerland|first17=Andrew M.|last18=Summers|first18=Deborah V.|last19=Tirschwell|first19=David L.|title=Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association|journal=Stroke|volume=50|issue=12|year=2019|issn=0039-2499|doi=10.1161/STR.0000000000000211}}</ref><ref name="SanossianSaver2006">{{cite journal|last1=Sanossian|first1=Nerses|last2=Saver|first2=Jeffrey L.|last3=Liebeskind|first3=David S.|last4=Kim|first4=Doojin|last5=Razinia|first5=Tannaz|last6=Ovbiagele|first6=Bruce|title=Achieving Target Cholesterol Goals After Stroke|journal=Archives of Neurology|volume=63|issue=8|year=2006|pages=1081|issn=0003-9942|doi=10.1001/archneur.63.8.1081}}</ref></div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>*In patients older than 75 years of age with clinical [[Coronary heart disease|ASCVD]], it is reasonable to initiate moderate or high-intensity [[statin]] therapy after reviewing [[adverse effects]] and [[Drug interaction|drug interactions]].<ref name="PowersRabinstein2019">{{cite journal|last1=Powers|first1=William J.|last2=Rabinstein|first2=Alejandro A.|last3=Ackerson|first3=Teri|last4=Adeoye|first4=Opeolu M.|last5=Bambakidis|first5=Nicholas C.|last6=Becker|first6=Kyra|last7=Biller|first7=José|last8=Brown|first8=Michael|last9=Demaerschalk|first9=Bart M.|last10=Hoh|first10=Brian|last11=Jauch|first11=Edward C.|last12=Kidwell|first12=Chelsea S.|last13=Leslie-Mazwi|first13=Thabele M.|last14=Ovbiagele|first14=Bruce|last15=Scott|first15=Phillip A.|last16=Sheth|first16=Kevin N.|last17=Southerland|first17=Andrew M.|last18=Summers|first18=Deborah V.|last19=Tirschwell|first19=David L.|title=Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association|journal=Stroke|volume=50|issue=12|year=2019|issn=0039-2499|doi=10.1161/STR.0000000000000211}}</ref><ref name="SanossianSaver2006">{{cite journal|last1=Sanossian|first1=Nerses|last2=Saver|first2=Jeffrey L.|last3=Liebeskind|first3=David S.|last4=Kim|first4=Doojin|last5=Razinia|first5=Tannaz|last6=Ovbiagele|first6=Bruce|title=Achieving Target Cholesterol Goals After Stroke|journal=Archives of Neurology|volume=63|issue=8|year=2006|pages=1081|issn=0003-9942|doi=10.1001/archneur.63.8.1081}}</ref></div></td></tr>
</table>
Hasnain Ali